Latest news with #CardinalHealth
Associated Press
2 days ago
- Business
- Associated Press
Cardinal Health launches new medical device for the continuous monitoring of three essential vital signs in one system
Kendall DL™ Multi System simplifies patient monitoring, drives efficiencies for providers DUBLIN, Ohio, June 4, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today the U.S. launch of its multi-parameter, single-patient use monitoring cable and lead wire system that enables the continuous monitoring of cardiac activity, blood oxygen level and temperature with one point of connection. The new Kendall DL™ Multi System is designed to travel with the patient from admission to discharge for smooth transport. It helps improve clinician workflows, provides reliable monitoring to help determine the best course of care, and maximizes value across the hospital. 'This innovative addition to the Kendall DL portfolio removes complexity for busy care teams, and at the same time, helps enhance clinical performance with multi-parameter monitoring,' said Rachel Schott, global vice president for specialty products at Cardinal Health. 'The product streamlines steps that clinicians must follow to provide effective care and controls common lead wire clutter with its built-in cable management system.' The Kendall DL™ Multi System offers a proprietary design that features clinically proven technology to reduce the incidence of false 'leads off' alarms2 (i.e., indications that wires connected to the patient's body are not properly connected), as well as motion-related artifacts in electrocardiogram (ECG) tracings,† which are recorded disturbances due to a patient's movement. This yields cleaner ECG tracings and allows clinicians to more effectively prioritize the care they need to administer. As a single-patient use product, the system helps reduce cross contamination related to reusable lead wires for the monitoring of cardiac activity, blood oxygen level and temperature.1 This helps lower the chance of infection and the need for additional hospital days or readmissions.3 The system is eligible for medical device reprocessing through Cardinal Health. 'By enabling more efficient workflows and driving clinical excellence, this new solution can potentially support the financial performance of healthcare providers,' Schott said. 'Expanding our Kendall DL offerings demonstrates our commitment to providing products designed to address multiple clinical and operational challenges across healthcare organizations, and builds upon our legacy of safe, high-quality patient monitoring solutions providers have come to trust.' The Kendall DL™ Multi System is now available for health systems in the U.S. For more information, please visit us here. About Cardinal Health Cardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuclear pharmacies and manufacturing facilities; and a provider of performance and data solutions. Our company's customer-centric focus drives continuous improvement and leads to innovative solutions that improve people's lives every day. Learn more about Cardinal Health at and in our Newsroom. Contacts References: †Cardinal Health Data on File – OEM Grabber Comparisons Report, Dec 2024 1. Brown DQ. Disposable vs reusable electrocardiography leads in development of and cross contamination by resistant bacteria. Crit Care Nurse. 2011 Jun;31(3):62 8. doi: 10.4037/ccn2011874. PMID: 21632593. 2. Albert N, Murray T, Bena J, et al. Differences in alarm events between disposable and reusable electrocardiography lead wires. Am J Crit Care. 2015 Jan;24(1):67-73; quiz 74. doi: 10.4031/ajcc2015663. 3. Saunders R, Hansson Hedblom A. The economic implications of introducing single patient ECG systems for cardiac surgery in Australia. Clinicoecon Outcomes Res. 2021 Aug 13;13:727-735. doi: 10.2147/CEOR.S232527 View original content to download multimedia: SOURCE Cardinal Health
Axios
2 days ago
- Business
- Axios
28 Ohio companies make 2025 Fortune 500 list
Nearly 30 of the country's top-grossing companies call Ohio home — including 10 in Northeast Ohio — according to the 2025 Fortune 500 list released Monday. Why it matters: Fortune 500 companies boost the state's economy, influence policy priorities and power job growth. Ohio's top-ranked companies, by fiscal year 2024 revenue, are: 15. Cardinal Health (Dublin): $226.8 billion — down 1 spot from last year. 27. Kroger (Cincinnati): $147.1 billion — down 2 spots. 29. Marathon Petroleum (Findlay): $140.4 billion — down 5. 51. Procter & Gamble (Cincinnati): $84 billion — down 1. Zoom in: Northeast Ohio's top-ranked company is Progressive (57), but Sherwin-Williams (191), Parker-Hannifin (215), Cleveland-Cliffs (221) and Goodyear (223) all landed in the top 250. Cleveland's KeyCorp (436) and Mentor's Avery Dennison (445) are further down the list, with revenue less than $10 billion. The intrigue: Cleveland military aircraft components manufacturer TransDigm (475) leaped 62 spots from last year's ranking. The big picture: Walmart topped the magazine's annual list for the 13th straight year. Amazon, UnitedHealth Group, Apple and CVS Health round out the top five.
Yahoo
4 days ago
- Business
- Yahoo
Cardinal Health, Inc. (NYSE:CAH) is favoured by institutional owners who hold 89% of the company
Institutions' substantial holdings in Cardinal Health implies that they have significant influence over the company's share price The top 20 shareholders own 51% of the company Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. A look at the shareholders of Cardinal Health, Inc. (NYSE:CAH) can tell us which group is most powerful. We can see that institutions own the lion's share in the company with 89% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute. In the chart below, we zoom in on the different ownership groups of Cardinal Health. See our latest analysis for Cardinal Health Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. As you can see, institutional investors have a fair amount of stake in Cardinal Health. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Cardinal Health, (below). Of course, keep in mind that there are other factors to consider, too. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. We note that hedge funds don't have a meaningful investment in Cardinal Health. Our data shows that BlackRock, Inc. is the largest shareholder with 13% of shares outstanding. The Vanguard Group, Inc. is the second largest shareholder owning 13% of common stock, and State Street Global Advisors, Inc. holds about 5.5% of the company stock. After doing some more digging, we found that the top 20 have the combined ownership of 51% in the company, suggesting that no single shareholder has significant control over the company. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. Our data suggests that insiders own under 1% of Cardinal Health, Inc. in their own names. Being so large, we would not expect insiders to own a large proportion of the stock. Collectively, they own US$140m of stock. Arguably recent buying and selling is just as important to consider. You can click here to see if insiders have been buying or selling. With a 10% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Cardinal Health. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. To that end, you should be aware of the 1 warning sign we've spotted with Cardinal Health . If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
18-05-2025
- Business
- Yahoo
Jim Cramer On Cardinal Health (CAH) 'They Are Impressive'
We recently published a list of . In this article, we are going to take a look at where Cardinal Health, Inc. (NYSE:CAH) stands against other stocks that Jim Cramer discussed recently. On Wednesday's episode of Mad Money, Jim Cramer reviewed the recent developments affecting drug distribution companies and laid out why he is turning cautious on the group. He pointed out that stocks of major drug distributors have retreated from their all-time highs. 'Most of the time, that's because of vague, amorphous concerns that some type of regulatory crackdown will force them out of business or, at the very least, make them a lot less profitable.' READ ALSO Jim Cramer Put These 8 Stocks Under a Microscope Recently and Jim Cramer Commented on These 6 Natural Gas Players Cramer referenced the executive order signed by the President last week aimed at lowering drug prices, which triggered a sell-off across the drug distribution sector. He explained that the order would effectively require pharmaceutical companies to offer the U.S. government drug prices that match the lowest rates charged in other advanced economies. Cramer said the market's fear is straightforward: if drugmakers are forced to cut prices for their government customers, then drug distributors could see their margins shrink. 'The bottom line: No matter how well the drug distributors have been doing, I do not want to stick my neck out for an industry that now seems to be hated by both the Democrats and the Republicans. It seems like the only thing they agree on, doesn't it? There are so many potential winners in this market, I say, why take the risk?' For this article, we compiled a list of 8 stocks that were discussed by Jim Cramer during the episodes of Mad Money aired on May 14. We listed the stocks in the order that Cramer mentioned them. We also provided hedge fund sentiment for each stock as of the fourth quarter of 2024, which was taken from Insider Monkey's database of over 1,000 hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A senior physician in a modern healthcare institution administering medication to a patient. Number of Hedge Fund Holders: 63 Cramer recommended buying Cardinal Health, Inc. (NYSE:CAH) because of its 'value-added services'. 'These stocks, namely Cardinal Health, Cencora, and McKesson, are seemingly perpetual residents on the new high list. Over the long haul, they're some of the best performers out there, and they've done great this year, as is pretty much always the case. And yet, doesn't it always feel like the drug distributors are just one bad day away from falling apart… Let's not forget that the drug distributors are making fortunes right now. Cardinal Health turned in an excellent set of numbers two weeks ago with double-digit earnings growth. Management put through a big boost in their full-year earnings forecast. Cardinal stock jumped 3% in response, climbing from $141 to $145, and it kept running for really a week after that, eventually setting at an all-time high of $154 just last Thursday. What a fabulous move… Cardinal Health (NYSE:CAH) supplies healthcare products and services across different care environments. It offers pharmaceuticals, medical equipment, and support solutions. The company also handles logistics, pharmacy operations, and distribution using technology across the healthcare sector. Overall, CAH ranks 4th on our list of stocks that Jim Cramer discussed recently. While we acknowledge the potential of CAH as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than CAH but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Business
- Yahoo
CAH Q1 Earnings Call: Cardinal Health Misses Revenue Targets but Exceeds Profit Expectations Amid Tariff Headwinds
Healthcare distributor and services company Cardinal Health (NYSE:CAH) fell short of the market's revenue expectations in Q1 CY2025, with sales flat year on year at $54.88 billion. Its non-GAAP profit of $2.35 per share was 9.4% above analysts' consensus estimates. Is now the time to buy CAH? Find out in our full research report (it's free). Revenue: $54.88 billion vs analyst estimates of $55.46 billion (flat year on year, 1% miss) Adjusted EPS: $2.35 vs analyst estimates of $2.15 (9.4% beat) Adjusted EBITDA: $849 million vs analyst estimates of $876.8 million (1.5% margin, 3.2% miss) Adjusted EPS guidance for the full year is $8.10 at the midpoint, beating analyst estimates by 1.7% Operating Margin: 1.3%, in line with the same quarter last year Free Cash Flow was $2.79 billion, up from -$161 million in the same quarter last year Market Capitalization: $35.42 billion Cardinal Health's Q1 results reflected a business in transition, as revenue came in just below Wall Street expectations while non-GAAP profit surpassed analyst forecasts. Management pointed to continued growth across its Pharmaceutical and Specialty Solutions segment, contributions from recent acquisitions, and operational improvements in its Global Medical Products and Distribution (GMPD) business as key performance drivers. The company also highlighted progress in onboarding new customers and expanding higher-margin services, which offset some external headwinds. Looking ahead, Cardinal Health raised its non-GAAP EPS guidance for the year, citing strong demand for specialty pharmaceuticals, growth in at-Home Solutions, and early benefits from the integration of Advanced Diabetes Supply Group. Management noted ongoing cost control efforts and investments in U.S. manufacturing and automation, but remained cautious about tariff-related risks and the impact of regulatory changes. CEO Jason Hollar emphasized that, 'the largest and highest growth parts of our business are resilient and well positioned to continue growth,' while acknowledging the company's focus on mitigating the financial impact of tariffs in GMPD. Management attributed the quarter's performance to resilient pharmaceutical demand, effective cost control, and growth in targeted business areas. The company's ability to manage through supply chain challenges and tariffs, while integrating new acquisitions, was a recurring theme. Specialty segment momentum: Growth in specialty pharmaceuticals and new customer onboarding, including the successful addition of Publix, drove segment profit. Specialty now represents a growing portion of the overall business mix, aided by acquisitions of GI Alliance and Integrated Oncology Network. GMPD turnaround progress: The GMPD segment saw improved profitability from operational efficiencies and cost reduction initiatives, with Cardinal Health branded products showing above-average growth compared to national brands. Tariff mitigation strategies: Management discussed aggressive steps to reduce tariff exposure, including expanding U.S. manufacturing, diversifying supply chains, leveraging tariff exemptions (such as the Nairobi protocol), and using artificial intelligence for compliance and planning. Most tariff costs in GMPD are expected to be addressed through operational actions and selective price adjustments. Integration of acquisitions: The company reported early positive contributions from GI Alliance, Integrated Oncology Network, and the Advanced Diabetes Supply Group, particularly in expanding higher-margin revenue streams and specialty care capabilities. Growth in high-margin segments: Other growth businesses, including At-Home Solutions, Nuclear, and OptiFreight, delivered double-digit profit growth. Management highlighted secular trends such as increased outpatient care and the demand for nuclear medicine as supportive of future performance. Cardinal Health's management anticipates continued earnings growth driven by demand for specialty pharmaceuticals, ongoing cost discipline, and successful integration of recent acquisitions, but flagged tariffs and regulatory actions as areas of uncertainty. Specialty and biologics expansion: The company expects further growth in specialty pharmaceutical distribution, including both upstream (manufacturer partnerships) and downstream (services to physician practices) businesses, bolstered by recent acquisitions. Tariff exposure and mitigation: While most business lines are not significantly impacted by tariffs, GMPD remains exposed. Management aims to offset the majority of gross tariff costs through cost-cutting and price adjustments, but some uncertainty remains regarding regulatory changes and the final financial burden. Operational investments: Strategic investments in automation, technology, and U.S.-based manufacturing are intended to improve efficiency and support long-term growth, while integration of new businesses (such as Advanced Diabetes Supply Group) is expected to enhance profitability and expand the service portfolio. Lisa Gill (JPMorgan): Asked about sustainability of specialty and branded sales growth; management pointed to broad-based demand and consistent growth across product lines, noting that recent customer wins are expected to support ongoing momentum. Allen Lutz (Bank of America): Questioned whether tariffs or macroeconomic weakness were affecting prescription volumes; CEO Jason Hollar replied that pharmaceutical demand remains resilient even during broader economic downturns, citing historical trends. Joanna Dynak (Evercore ISI): Requested details on Cardinal Health branded GMPD revenue and tariff recovery; management declined to share profit mix specifics but noted strong branded product growth and ongoing use of tariff exemptions. Eric Percher (Nephron): Sought clarification on how much of the $200–$300 million in GMPD tariff costs could be offset by pricing; management expects the majority to be addressed through price increases, especially on Cardinal Health branded products. Daniel Grosslight (Citi): Asked about the practical ability to pass on price increases given customer contracts; management said most price adjustments would follow operational mitigation, and efforts would focus on collaboration with customers to avoid supply disruptions. Looking ahead, the StockStory team will monitor (1) Cardinal Health's ability to sustain specialty pharmaceutical growth and integrate new customer wins, (2) the effectiveness of tariff mitigation strategies within GMPD, and (3) progress in expanding higher-margin businesses such as At-Home Solutions and Nuclear. Updates at the upcoming Investor Day and further color on regulatory or tariff actions will also be important indicators of future performance. Cardinal Health currently trades at a forward P/E ratio of 17×. Is the company at an inflection point that warrants a buy or sell? See for yourself in our free research report. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
